Step by Step

INTRODUCTION

ABIM MOC Activity ID

3/14/2017 MGR: Randomized trials of chemotherapy for hormone-naïve metastatic prostate cancer: be careful what you wish for & Endocrine therapy duration updates: too much of a good thing?

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe data supporting early chemotherapy in metastatic prostate cancer.
  • Review selection of patients for early chemotherapy for metastatic prostate cancer.
  • Identify risk factors for chemotherapy toxicity.
  • Review history of endocrine treatment
  • Describe difference in pre and post menopausal breast cancer.
  • Review new and updates in hormonal therapy.

Suggested Additional Reading:

  1. Gnant, et al, Brit J Cancer, 2013.
  2. Burstein HJ. J Clin Oncol 2014 32(21):2255-69.

Authors:
Leonard Appleman, MD, PhD — Associate Professor of Medicine Division of Hematology/Oncology, UPMC
Dr. Appleman receives grant/research support from Astellas BMS Bayer, Exelixis, Medivation, Cougar, Agensys, Pfizer, and Roche.
Shannon Puhalla, MD — Assistant Professor of Medicine Division of Hematology/Oncology, UPMC
Dr. Puhalla receives grant/research support from Abbvie, Pfizer, Lilly, Novartis, Incyte, Covance-Bayer, Eisai. She is a consultant with Abbvie, Medimmune, Alldex, and a board member with Alldex (DSMB)
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.